Human Response Platform will be utilized to identify genetic profiles of patients most likely to benefit.
Eli Lilly will use Aveo Pharmaceuticals’ technology to more effectively guide the clinical development of one of its cancer compounds.
Under the collaboration, Lilly will use the Human Response Platform as part of a pilot project. Lilly hopes to identify genetic profiles that correlate with drug response.
“This latest collaboration with a global pharmaceutical company indicates the opportunity that our platform provides our select partners and AVEO to increase the efficiency and probability of success of drug development in oncology,” points out Tuan Ha-Ngoc, president and CEO of Aveo. “Ultimately, we believe this will enable us to bring the right drugs to the right patients.”